The Netherlands is often underestimated. With more than 18 million people, it is still one of Europe's smaller healthcare markets by population. Yet it sits among the largest medtech hubs on the continent, running one of Europe's biggest medical device trade surpluses, medical device exports of roughly €34 billion against €27 billion in imports in 2024, according to MedTech Europe, anchored by the Port of Rotterdam and Schiphol as gateways into the wider European market.
But the reason medtech companies pay attention to the Netherlands has little to do with size.
The country combines a dense innovation ecosystem, a highly organised healthcare system and a position as one of Europe's most demanding proving grounds for evidence. It is a market where access is rarely won on technology alone, and where succeeding can shape how a product is perceived across the rest of Europe.
The Netherlands Functions Less as a Market Than as a System
The Dutch healthcare system is frequently cited internationally as a model of managed competition, a design that tries to combine universal access with market mechanisms.
Everyone who lives or works in the Netherlands is required to hold basic health insurance from a private insurer, with the content of that basic package defined by the government rather than by individual insurers. Insurers compete on premium and service, but must accept all applicants and cover the same statutory package. The intention is that competition acts on price and quality without compromising universal access.
For medtech companies, this has a specific consequence: the insurers are not a fragmented field of buyers with divergent logic. They are purchasers operating inside a single, centrally defined framework. Understanding that framework matters more than mapping individual accounts.
The system rests on several statutes that determine where a technology fits:
- Zvw (Health Insurance Act) - curative care delivered by GPs, hospitals and pharmacies
- Wlz (Long-Term Care Act) - long-term and residential care
- Wmo (Social Support Act) - municipally organised social and in-home support
- Jeugdwet (Youth Act) - care for children and adolescents
Where a technology lands across these statutes shapes who pays for it, how it is procured and what evidence is required. A home-monitoring solution may sit very differently under the Zvw than under the Wlz or Wmo, and that placement can determine the entire commercialisation path.
Reimbursement is Gated by Evidence, Not by Novelty
In the Netherlands, the central question is rarely whether a technology is innovative. It is whether the technology meets the "state of science and practice", the statutory bar for inclusion in the basic package.
Two institutions shape this landscape:
Zorginstituut Nederland (ZIN) - the National Health Care Institute, which advises on and clarifies what belongs in the basic package, and assesses whether care is effective enough to be reimbursed.
Nederlandse Zorgautoriteit (NZa) - the healthcare authority, which regulates tariffs and the structures through which providers are paid.
Much of Dutch hospital care is funded through bundled care-product tariffs (the DBC system), which means a novel technology often needs to find its place within an existing payment structure rather than arriving with one of its own. For technologies without a clear path into established tariffs, this can create the same kind of friction seen in other systems: clinical interest exists, but the route to sustainable payment is unclear.
The evidence bar is deliberately high. Inclusion in the basic package depends on demonstrating that care does what it is meant to do, and the assessment process is careful, structured and rarely fast.
The Netherlands has Built Pathways for Evidence That Doesn't Yet Exist
Rather than leaving promising-but-unproven technologies stranded, the Dutch system has developed mechanisms to generate the evidence it requires.
Instruments such as conditional inclusion and the more recent "Reimbursement within Research" approach allow certain technologies to be temporarily funded under basic insurance while effectiveness and cost-effectiveness data are collected. The data generated then feeds back into the decision on permanent inclusion.
This reflects something distinctive about the Dutch approach. The system does not simply demand evidence as a gate - it actively structures the conditions under which that evidence can be produced. For medtech companies at earlier stages of clinical maturity, these pathways can be strategically important: they convert the evidence requirement from a barrier into a defined, navigable process.
It also signals what the system values. Real-world evidence, cost-effectiveness and demonstrated appropriateness of care tend to carry more weight than premium positioning or technological sophistication alone.
The GP Gatekeeper Shapes Where Value Has to be Proven
A defining feature of Dutch healthcare is the role of the general practitioner (GP) as gatekeeper. Patients generally access specialist and hospital care through a referral from their GP, who sits at the centre of primary care.
This has consequences that are easy to overlook from the outside. Strong primary care, combined with a long-standing policy emphasis on "the right care in the right place" (Juiste Zorg op de Juiste Plek), creates structural pressure to move care out of hospitals and closer to the patient, into primary care, community settings and the home.
For medtech companies, this changes where value must be demonstrated. Technologies that support diagnosis, monitoring or treatment outside the hospital, and that reduce unnecessary referrals or admissions, align with the direction the system is actively trying to move in. Solutions that only add cost or complexity at the hospital tier face a steeper path.
Innovation Concentrates Around a High-Tech Ecosystem, Not a Capital
While Dutch healthcare delivery is organised nationally, medtech innovation concentrates heavily around the Brainport Eindhoven region. Built on foundations laid by Philips, the area hosts hundreds of medtech companies and is associated with the large majority of Dutch medtech patents and a substantial share of the country's life sciences output.
What distinguishes this ecosystem is less any single institution than the way it is wired together. The Netherlands relies on a triple helix model, government, knowledge institutions and industry working in deliberate coordination, and Eindhoven is its clearest expression.
Collaborations such as the Eindhoven MedTech Innovation Center (e/MTIC), which links the technical university with hospitals and industry around shared clinical domains, illustrate the logic: research, clinical validation and commercialisation are designed to sit close together. For companies, this can shorten the distance between an early-stage technology and a credible clinical testing environment.Beyond Eindhoven, academic medical centres in Amsterdam, Utrecht, Rotterdam, Leiden and Groningen anchor clinical research, while the country's strong logistics and manufacturing base supports its role as a European distribution gateway.
Trust Opens the Door - But the System Decides Whether it Scales
European and particularly Northern European medtech is often associated with strong engineering and clinical quality, and the Dutch system is receptive to that credibility. Validation in a Dutch academic centre or a leading clinical collaboration can carry weight well beyond the country's borders.
But the Netherlands rewards a specific kind of fit. The system is organised, evidence-driven and cost-conscious, with insurers, the NZa and ZIN each applying structured logic to whether and how a technology belongs. Clinical enthusiasm from individual specialists is rarely sufficient on its own.
Companies that succeed tend to treat the Dutch market as a system to be understood rather than a set of accounts to be sold into. They identify early where their technology fits across the statutory framework, what evidence the relevant pathway requires, and how the technology supports - rather than resists - the shift toward appropriate care and care closer to home.
Reform is Moving the System Toward Integration and Data
The direction of Dutch healthcare policy reinforces these dynamics. The Integraal Zorgakkoord (IZA), a cross-sectoral care agreement reached in 2022, with a supplementary agreement following in 2025, reflects mounting pressure from rising costs, workforce shortages and an ageing population.
The emphasis is on prevention, regional collaboration across care domains, and reducing avoidable demand on the system. This continues to favour technologies that improve efficiency, enable care outside the hospital and demonstrably reduce strain on a stretched workforce.
In parallel, the Netherlands is preparing for the European Health Data Space (EHDS), alongside its own investments in health data infrastructure. For data-driven and AI-enabled technologies, this signals a system increasingly oriented toward interoperability and the structured use of health data at scale, though it also raises the bar for how such technologies handle evidence, validation and integration.
Why the Netherlands is a Test of System Fit, Not Market Size
The Netherlands is not a market a company enters for volume. It is a market companies enter because succeeding there means something.
It is a system where universal access is combined with managed competition, where reimbursement is gated by a demanding evidence standard, where care is being deliberately pushed closer to the patient, and where innovation is wired together through close collaboration between industry, academia and the clinic. None of these elements operates in isolation, financing, evidence, adoption and policy direction are tightly interconnected.
For medtech companies, the strategic question is rarely whether the Dutch market is large enough. More often, it becomes:
Does the technology fit the system? Can it meet the evidence bar, or use the pathways built to generate it? And does it move in the same direction the system is already heading?
The opportunity in the Netherlands is not simply access to one European market. It is the chance to prove, in one of Europe's most structured and demanding healthcare systems, that a technology genuinely fits how modern healthcare is being built.
This article is part of our internationalisation series exploring how healthcare systems, reimbursement structures and market dynamics shape medtech commercialisation across different global markets. You can also explore our foundational article on international medtech expansion.
Served by Medtech Maze